MarketPeel
Insider Trading Intelligence
Pricing
…
RB

Romulus K. Brazzell

KALA
SEE REMARKS · KALA BIO, INC. · CIK 0001298079
FILING MIX · LIFETIME42%/58%
BUYS
18
SELLS
25
TOTAL VALUE
$393.8K
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
35,952
AVG SELL PX
$2.13
TRADE KIND
SHOWING 43 / 43
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Romulus K. Brazzell, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+61.54%-2.11%+0.64%-2.74%-5.85%—
14d13+46.15%+0.73%+0.94%-0.21%+0.70%—
30d13+53.85%+0.30%+2.62%-2.33%-6.37%—
60d13+69.23%-0.31%+2.71%-3.02%-23.89%—
90d13+53.85%+36.17%+2.26%+33.91%-18.57%—
180d13+76.92%+221.56%+7.03%+214.53%-56.98%—
1y13(1 pending)+58.33%+677.98%+8.78%+739.83%-15.38%—
2y13(4 pending)+77.78%-19.78%+30.24%-44.14%-87.51%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KALA · 35,952 shares · as of Oct 22, 2025
075,999151,998227,997303,99620212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
FLOW · 18 buys / 25 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KALA
KALA BIO, INC.
SALE
SEE REMARKS
46,748$0.83$38.8K35,952Oct 22, 2025Oct 24, 2025 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
5,251$4.01$21.1K82,698Jun 24, 2025Jun 26, 2025 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
3,687$3.74$13.8K87,949Jun 3, 2025Jun 4, 2025 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
45,200——45,200Jan 6, 2025Jan 7, 2025 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
10,100——94,864Jan 6, 2025Jan 7, 2025 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
2,446$7.63$18.7K92,418Jan 6, 2025Jan 7, 2025 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
5,489$4.75$26.1K83,982Jun 26, 2024Jun 27, 2024 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
2,002$6.09$12.2K89,471May 31, 2024Jun 3, 2024 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
1,617$6.74$10.9K91,473Jan 4, 2024Jan 5, 2024 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
6,500——93,090Jan 4, 2024Jan 5, 2024 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
29,300——29,300Jan 4, 2024Jan 5, 2024 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
49,356——85,808Jun 22, 2023Jun 23, 2023 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
65,808——65,808Jun 22, 2023Jun 23, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
2,199——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
864——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
4,759——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
942——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
1,399——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
2,399——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
17,916——36,452May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
2,999——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
2,047——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
308——0May 31, 2023Jun 2, 2023 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
576——576Mar 14, 2023Mar 15, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
73$28.53$2.1K18,536Jan 4, 2023Jan 6, 2023 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
12,800——18,609Jan 4, 2023Jan 6, 2023 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
261$6.51$1.7K5,809Oct 26, 2022Oct 28, 2022 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
3,144$0.37$1.2K285,201Jun 27, 2022Jun 29, 2022 ↗View →
KALA
KALA BIO, INC.
SALE
SEE REMARKS
3,504$1.30$4.6K288,345Jan 4, 2022Jan 5, 2022 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
238,000——238,000Jan 3, 2022Jan 5, 2022 ↗View →
KALA
KALA BIO, INC.
SALE
CHIEF MEDICAL OFFICER
12,757$1.80$23.0K291,849Oct 26, 2021Oct 28, 2021 ↗View →
KALA
KALA BIO, INC.
SALE
CHIEF MEDICAL OFFICER
3,034$5.77$17.5K300,962Jun 28, 2021Jun 29, 2021 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
110,000——110,000Jan 4, 2021Jan 5, 2021 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
27,500——303,996Jan 4, 2021Jan 5, 2021 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
81,000——276,496Oct 26, 2020Oct 28, 2020 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
19,000——195,496Jun 25, 2020Jun 29, 2020 ↗View →
KALA
KALA BIO, INC.
PURCHASE
Chief Medical Officer
47,644$3.34$159.1K176,496Apr 9, 2020Apr 13, 2020 ↗View →
KALA
KALA BIO, INC.
SALE
Chief Medical Officer
1,880——0Apr 9, 2020Apr 13, 2020 ↗View →
KALA
KALA BIO, INC.
SALE
Chief Medical Officer
47,644——13,508Apr 9, 2020Apr 13, 2020 ↗View →
KALA
KALA BIO, INC.
PURCHASE
Chief Medical Officer
18,247$2.30$42.0K128,852Apr 9, 2020Apr 13, 2020 ↗View →
KALA
KALA BIO, INC.
SALE
Chief Medical Officer
18,247——0Apr 9, 2020Apr 13, 2020 ↗View →
KALA
KALA BIO, INC.
PURCHASE
Chief Medical Officer
1,880$0.68$1.3K110,605Apr 9, 2020Apr 13, 2020 ↗View →
KALA
KALA BIO, INC.
PURCHASEGRANT
Stock grant
120,000——120,000Jan 2, 2020Jan 3, 2020 ↗View →
Other insiders · KALA
Loading peer insiders…
About this filer
CIK 0001298079
ROLE
SEE REMARKS
PRIMARY
KALA
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001298079DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback